Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2020-03-01
Serie:International Journal of Molecular Sciences
Soggetti:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Accesso online:https://www.mdpi.com/1422-0067/21/7/2275
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi